Isotechnika Pharma Inc IPHAF

A new group of investors has found ISA

[professional11]

After an application is accepted, the company (in this case ISA) gets evaluated by a whole new group of investors.  This group specializes in predicting the likelihood of approval - they do their research and invest accordingly.

Clearly, this new group of investors is expecting Voclosprine to be approved -and there are many reasons for that:

1) Orphan indication, significantly increases the odds
2) Next-gen therapeutic, mildly increases the odds
3) Been in 1000s of patients already, dramatically increases the odds
4) Applied to EMEA and  FDA, two shots on goal is better than one
5) Opthamology indication, significantly increases the odds

The likelihood of this penny stock making money in the next 12 months is very high - and they know it. 

P11

[professional11]

For those interested, below are potential outcomes for ISA in October:—First, the FDA could approve the drug with some standard warnings but not a black box warning, the stock price goes up significantly -75% probability —Second, the FDA may approve the drug with a Black Box warning. If this happens, the stock will still go up, but investors may fret - 5% probability—Third

[labumba]

not agree.....it is a ROLLING review process as for an orphanage status drug.....means drug will get fast approval to be on the market, pershaps, with some warnings but not in the scenario of starting another trial unless the  results from Psoriasis trials are  "cooked "